Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-18
2006-07-18
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S398000, C544S139000, C548S333100
Reexamination Certificate
active
07078401
ABSTRACT:
Methods for treatment of IP antagonist mediated diseases or conditions by administration to a subject in need thereof a compound of formula (I)wherein R1, R2, A and X are as defined herein. Also disclosed are compounds and related compositions.
REFERENCES:
patent: 4374143 (1983-02-01), Dolman et al.
patent: 4396617 (1983-08-01), Dolman et al.
patent: 6184242 (2001-02-01), Bley et al.
patent: 6417186 (2002-07-01), Jahangir
patent: 6472536 (2002-10-01), Bley et al.
patent: 6596876 (2003-07-01), Bley et al.
patent: 0 901 018 (1999-03-01), None
patent: WO 02/40453 (2002-05-01), None
Ito et al. Chem. & Pharm. Bull. 1960, 7, 605 *(CAS Abstract Attached).
Clarke, Robin D., “Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists”,Bioorganic&Medicinal Chemistry Letters, 14(4) 1053-1056, Feb. 23, 2004.
Bley Keith Roger
Clark Robin Douglas
Jahangir Alam
Hall Robert C.
Nolan Jason M.
Roche Palo Alto LLC
Saeed Kamal A.
LandOfFree
Thiophenylaminoimidazolines as IP antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiophenylaminoimidazolines as IP antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophenylaminoimidazolines as IP antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595962